A Chance to Reflect and Look Forward
Highlighting a year of conference coverage for ACT.
Over the past few weeks, signs of 2023 coming to an end are aplenty; the temperatures have fallen, and holidays are beginning to appear more frequently on the calendar. I’m sure I’m not alone in feeling that the end of each year serves as a good time to reflect on the previous 12 months. For Applied Clinical Trials, there have been many bright spots throughout 2023. One in particular I’d like to highlight here is our conference coverage—a pillar of our many brands at MJH Life Sciences®. ACT was front and center at several of this year's largest industry conferences, including the Summit for Clinical Ops Executives (SCOPE) North America, SCOPE Europe (see our executive roundtable from the event here), DPHARM, and the DIA Annual Meeting. Our editors did a fantastic job in providing timely coverage of breakout sessions and speaking with industry leaders for video interviews. All of the content can be found here on our website:
www.appliedclinicaltrialsonline.com/latest-conference. We look forward to continuing our coverage of these events in 2024.
Not to be overlooked, of course, are present happenings. For this December issue of ACT, we focus on novel clinical trial designs. From basket trials, to using real-world evidence (RWE), and master protocols, there are many new elements to trial design. We explore some of these design approaches and how regulatory authorities are moving the needle on their acceptance.
Our first feature examines the benefits of early protocol assessment in boosting patient centricity. For example, with so many new design elements in the fold, getting ahead of potential pitfalls can greatly reduce patient burden while expanding opportunities to apply clinical data on a wider scale.
Following is a feature looking at innovation in clinical trials for chimeric antigen receptor (CAR) T-cell therapies. These products have steadily demonstrated positive results for oncology patients in recent years. The article focuses on next-step, digitally driven pursuits for CAR T-cell trials and how this area can be advanced further. Our final December feature discusses strategies for implementing digital protocols and ways to streamline processes such as content reuse, workflow animation, and study design.
As always, thank you for reading.
Mike Hennessy Jr, president and CEO, MJH Life Sciences®
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
